

## Structure of a Calcium-Independent Phospholipase-like Myotoxic Protein from *Bothrops asper* Venom

By R. K. ARNI AND R. J. WARD

*Department of Physics, UNEXSP-IBILCE, Cx.P. 136, 15054-000, São José do Rio Preto-SP, Brazil*

J. M. GUTIERREZ

*Instituto Clodomiro Picado, Universidad de Costa Rica, San José, Costa Rica*

AND A. TULINSKY

*Department of Chemistry, Michigan State University, East Lansing, USA*

(Received 23 March 1994; accepted 10 October 1994)

### Abstract

Myotoxin II, a myotoxic calcium-independent phospholipase-like protein isolated from the venom of *Bothrops asper*, possesses no detectable phospholipase activity. The crystal structure has been determined and refined at 2.8 Å to an *R* factor of 16.5% ( $F > 3\sigma$ ) with excellent stereochemistry. Amino-acid differences between catalytically active phospholipases and myotoxin II in the  $\text{Ca}^{2+}$ -binding region, specifically the substitutions  $\text{Tyr28} \rightarrow \text{Asn}$ ,  $\text{Gly32} \rightarrow \text{Leu}$  and  $\text{Asp49} \rightarrow \text{Lys}$ , result in an altered local conformation. The key difference is that the  $\epsilon$ -amino group of Lys49 fills the site normally occupied by the calcium ion in catalytically active phospholipases. In contrast to the homologous monomeric Lys49 variant from *Agkistrodon piscivorus piscivorus*, myotoxin II is present as a dimer both in solution and in the crystalline state. The two molecules in the asymmetric unit are related by a nearly perfect two-fold axis, yet the dimer is radically different from the dimer formed by the phospholipase from *Crotalus atrox*. Whereas in *C. atrox* the dimer interface occludes the active sites, in myotoxin II they are exposed to solvent.

### Introduction

Phospholipases A<sub>2</sub> (PLA<sub>2</sub>, E.C. 3.1.1.4) are small stable calcium-dependent hydrolytic enzymes that specifically hydrolyze the *sn*2 ester of phospholipids (Deenen & de Haas, 1964), preferentially in lamellar or micellar aggregates at membrane surfaces (reviewed by Ramírez & Jain, 1991). These enzymes are widely distributed in nature and have been extensively studied (Dennis, 1983; Waite, 1987). The extracellular PLA<sub>2</sub>'s occur abundantly in mammalian pancreatic juice and in the venoms of snakes and insects. The intracellular PLA<sub>2</sub>'s, which are often membrane associated, are involved in blood platelet aggregation and inflammation (Scott *et al.*,

1990). The catalytic activity of these intracellular enzymes results in the release of arachidonic acid, a precursor of eicosanoids, and is implicated in triggering inflammatory reactions (Scott *et al.*, 1990).

Despite the diversity of occurrence, the primary sequence of all PLA's demonstrate considerable sequence homology and are divided into two classes on the basis of location of disulfide bridges and loop lengths. Class I PLA<sub>2</sub>'s include pancreatic and elapid venom enzymes, whereas class II are found in crotalid and viper venom PLA<sub>2</sub>'s (Dufton & Hider, 1983).

Recently, a sub-class of snake-venom PLA<sub>2</sub>-like proteins which retain cytotoxicity, but lack phospholipase activity have been identified and sequenced (Maraganore *et al.*, 1984; Maraganore, Poorman & Heinrickson, 1987; Yoshizumi *et al.*, 1990; Liu *et al.*, 1990; Homsi-Brandenburgo, Queiroz, Santo-Neto, Rodrigues-Simon & Giglio, 1988; Francis, Gutierrez, Lomonte & Kaiser, 1991). In the catalytically active PLA<sub>2</sub>, calcium is an essential co-factor, and the non-catalytic PLA<sub>2</sub>-like proteins are primarily characterized by the substitution of Asp49 by Lys. In all catalytically active PLA<sub>2</sub>'s, Asp49 plays a central and essential role in catalysis by contributing two carboxylate O atoms to the calcium ligation cage. The Asp49 → Lys49 substitution results in the  $\epsilon$ -amino group of lysine filling the site normally occupied by the calcium ion (Holland *et al.*, 1990; Scott, Achari, Vidal & Sigler, 1992) resulting in the loss of calcium binding. Although initial results suggested that the Lys49 variant isolated from *Agkistrodon piscivorus piscivorus* (App) demonstrated a low level of PLA<sub>2</sub> activity (Maraganore *et al.*, 1984), it has subsequently been shown that this is due to trace contamination by other active PLA<sub>2</sub> species (Dhillon *et al.*, 1987; van den Berg, Slotboom, Verheij & de Haas, 1989).

The interaction of *Bothrops asper* myotoxin II with liposomes of diverse composition provokes rapid and

extensive release of the aqueous contents. Previous work (Rufini *et al.*, 1992) has established that, (a) this process is  $\text{Ca}^{2+}$  independent and occurs without detectable phospholipid hydrolysis. (b) Whereas catalytically active phospholipases are unable to induce liposome leakage in the absence of  $\text{Ca}^{2+}$ , the addition of  $\text{Ca}^{2+}$  results in liposome leakage with concomitant hydrolysis of phospholipids. (c) The kinetics of the  $\text{Ca}^{2+}$ -dependent and independent liposome leakage indicate the existence of different mechanisms of interaction with the lipid bilayer. In conclusion, it is suggested that a new type of cytolytic reaction mechanism is responsible for the effects of myotoxin II *in vivo* (Rufini *et al.*, 1992).

In the hope of providing an insight into this novel mechanism, we have determined the structure of myotoxin II, a myotoxic Lys49 variant from the venom of *B. asper*. The model we present has been determined at 2.8 Å resolution and refined to a crystallographic residual of 16.5% ( $F > 3\sigma$ ). The structural changes caused by amino-acid substitutions in the calcium-binding loop are examined and compared to the structure of the Lys49 variant from App. In addition, myotoxin II exists as a dimer in solution, and the structure we present here provides an insight as to the nature of the dimer interface.

### Experimental methods

The Lys49 PLA<sub>2</sub> from *B. asper* was isolated (Lomonte & Gutierrez, 1989) and the protein (5.0 mg ml<sup>-1</sup>) was crystallized from 0.1 M citrate, 20% 2-propanol using 20% PEG 4000 as a precipitant (Arni & Gutierrez, 1993). Crystals belong to space group  $P2_12_12_1$  with cell constants  $a = 50.18$ ,  $b = 67.76$  and  $c = 88.00$  Å.

X-ray diffraction data was collected from a single crystal using a Rigaku RU200 generator operated at 50 kV and 150 mA and a Xentronics area detector (Siemens). The data was processed using the program *XENGEN* (Howard *et al.*, 1987). An  $R_{\text{merge}}$  on intensities of 0.056 was obtained for 5805 unique reflections from a total of 23 021 observations. Table 1 summarizes the crystallographic data and refinement statistics.

The structure was solved by molecular-replacement techniques using the program package *MERLOT* (Fitzgerald, 1988). The search model, which consisted of 887 atoms, was derived from the Lys49 variant from App (Holland *et al.*, 1990). Structure factors were calculated in a cubic cell with *P1* symmetry and edge dimensions of 120 Å. Data with  $I > 3\sigma$  between 8.0 and 4.0 Å was used coupled with a radius of integration of 23.9 Å. The two highest peaks in the cross-rotation function map were  $6.2\sigma$  and  $4.5\sigma$ . Correlation with the self-rotation results revealed the orientation of the two molecules in the asymmetric unit. The orientation angles were refined using the Lattman rotation function (Lattman & Love, 1972) with angular increments of  $\alpha = 1.0$ ,  $\beta = 1.0$  and  $\gamma = 2.0^\circ$ . The highest peaks in the Crowther & Blow

Table 1. Summary of crystallography data and refinement statistics

Space group	$P2_12_12_1$
Cell constants (Å)	$a = 50.18(2)$ $b = 67.76(3)$ $c = 88.00(4)$
No. of observations	23021
No. of unique reflections	5805
$R_{\text{merge}}$	0.056
Refinement statistics	
Resolution (Å)	7.0–2.8
No. of reflections	4915
$R$ factor (%)	16.5
No. of protein atoms	1890
No. of solvent atoms	69
R.m.s. deviations from ideal values	
Bond lengths (Å)	0.010
Bond angles (°)	2.107
Dihedral (°)	27.948
Improper (°)	6.661

translation function (Crowther & Blow, 1967) with  $\sigma$  values between 7.9 and 5.0 produced a model with an acceptable number of close contacts. The rotational and translational parameters were optimized by utilizing the  $R$ -factor minimization procedure as implemented in *MERLOT* (Fitzgerald, 1988) which reduced the  $R$  factor from 52.0 to 48.1% in the 6.0–3.5 Å resolution range.

Energy minimization and refinement using *X-PLOR* (Brünger, 1988) resulted in an  $R$  factor of 23.9% in the 10.0–2.8 Å resolution range. The electron-density map was then examined using *FRODO* (Jones, 1985) and all the side-chain atoms were included. An additional round of simulated annealing resulted in a crystallographic residual of 21.2% (7.0–2.8 Å). Numerous simulated-annealing omit maps were computed to permit the determination of the conformation of poorly determined loop regions (see results) and three additional rounds of




Fig. 1. Ribbon representation of the structure the myotoxin II monomer. The N terminus (N) and C terminus (C) are labelled.

model building and refinement were carried out. The individual temperature factors were refined and the refinement converged to a final residual of 16.5% ( $F > 3\sigma$ ) for 4915 reflections between 7.0 and 2.8 Å. The final model consisted of 1890 protein atoms and 69 solvent O atoms.

## Results

The asymmetric unit of the myotoxin II crystal contains two monomers with near-perfect twofold rotational symmetry (see below). The ribbon diagram presented in Fig. 1 presents the fold of the myotoxin II monomer. The structure is similar to those of PLA<sub>2</sub>'s isolated from other snake species (Brunie, Bolin, Gewirth & Sigler, 1985; Holland *et al.*, 1990; White, Scott, Otwinowski, Gelb & Sigler, 1990; Freemont, Anderson, Wilson, Dennis & Xuong, 1993) and mammals (Dijkstra, Kalk, Hol & Drenth, 1981; Dijkstra, Renetseder, Kalk, Hol & Drenth, 1983; Wery *et al.*, 1991). Using the nomenclature and numbering scheme of Heinrikson, Kreuger & Keim (1977), myotoxin II is classified as a class II PLA. The structure is stabilized by seven disulfide bridges (27:125, 29:45, 44:105, 50:133, 51:98, 61:91, 84:96) and

comprises an N-terminal  $\alpha$ -helix (residues 2–12), linked by loops and a single helical turn to the first long  $\alpha$ -helix (40–55). A short antiparallel  $\beta$ -sheet (75–84), referred to as the  $\beta$ -wing, leads to a second long helix (90–107) which is antiparallel to the first. The loop region (25–35) corresponds to the calcium-binding loop in the enzymically active PLA<sub>2</sub>'s.

The deviations of bond lengths and angles from ideal values for the model are presented in Table 1. The Ramachandran plot (not shown) (Ramachandran & Sasisekharan, 1965) indicates the presence of two outliers. Fig. 2 illustrates the distribution of the temperature factors for sequentially numbered main-chain and side-chain atoms. The outliers in the Ramachandran plot lie in the same loop region in each of the two molecules (78–80 sequential numbering, 88–90 homology numbering). The loops contain a proline, possess higher than average temperature factors and are characterized by poor electron density.

Fig. 3 and Table 2 present the results of the superpositioning using the  $C\alpha$  atoms of the homologous core (Renetseder, Brunie, Dijkstra, Drenth & Sigler, 1985) from the two monomers in the asymmetric unit of myotoxin II and the structure of the Lys49 variant from App. The structures of the two monomers are very similar, and the largest deviations between the structures of myotoxin II and the Lys49 variant from App are mainly in the calcium-binding and the C-terminal loop regions.

## Dimer interactions

Myotoxin II exists as a highly stable dimer in solution (Francis *et al.*, 1991), and in the crystal structure the two




Fig. 2. Distribution of the mean temperature factors as a function of residue number. Thick and thin lines represent main-chain and side-chain atoms, respectively. The two molecules in the asymmetric unit are numbered sequentially from 1 to 121 and 201 to 321.




Fig. 3. Superpositioning of the  $C\alpha$  atoms from, myotoxin II molecule 1 (thick line), myotoxin II molecule 2 (thin line), and App (dashed line).

Table 2. Statistics derived from superpositioning the  $\text{C}\alpha$  atoms of the myotoxin II molecules 1 and 2 with App utilizing the homologous core as defined by Renetseder *et al.* (1985)

First molecule	Second molecule	R.m.s. deviation
Myotoxin II molecule 1	Myotoxin II molecule 2	0.587
Myotoxin II molecule 1	App	1.048
Myotoxin II molecule 2	App	1.100

monomers are related by an almost perfect twofold symmetry axis (rotation angle  $179.7^\circ$ ). We propose this crystallographic interaction is representative of the dimeric interaction in solution.

In catalytically active PLA<sub>2</sub>'s, it has been suggested that dimerization is essential and enhances enzymatic activity (Cho, Tomasselli, Heinrickson & Kezdy, 1988; Tomasselli *et al.*, 1989). Myotoxin II presents a novel dimeric form for PLA<sub>2</sub> molecules, as illustrated in Fig. 4(a). The  $\beta$ -wing regions interact closely with each other and the putative 'catalytic' sites are exposed to the solvent. These extensive and intimate diad interactions are mainly between the amino acids located at the C-terminal end of the first helix and the loop region preceding the first  $\beta$ -strand of the  $\beta$ -wing. Fig. 4(b) shows this region in more detail, and illustrates the interactions stabilizing the dimer. Table 3 provides a list of the amino-acid side chains participating in the stabilization of the dimer.

In contrast to the crystal structures of other PLA<sub>2</sub>'s, where the  $\beta$ -wing region is disordered (Scott *et al.*, 1992), these regions are well defined in the electron density of myotoxin II, presumably due to the extensive interactions which stabilize the dimer (Table 3). The amino acids involved in these interactions in the structure of myotoxin II are conserved in App Lys49 and are in the same relative orientations with the exception of the indole ring of Trp77. Interestingly, App Lys49 exists as a monomer in the two crystal structures reported (Holland *et al.*, 1990; Scott *et al.*, 1992), and this region has not been reported to be involved in the formation of intermolecular contacts (Holland *et al.*, 1990; Scott *et al.*, 1992).

In the crystal structure of dimeric PLA<sub>2</sub> from *Crotalus atrox*, the monomers are also related by a twofold rotational symmetry axis. However, in this case the interaction results in the formation of a very different dimer in which the catalytic residues are shielded from the solvent and face an internal cavity, and the  $\beta$ -wing region is fully exposed to the solvent. Additionally, the catalytically essential residue Asp49 forms hydrogen bonds between the two molecules (Brunie *et al.*, 1985). If this structure does indeed represent the functional dimer, and dimerization is essential for activity (Shen *et al.*, 1975), it is unclear how the dimers dissociate or reorient

Table 3. Amino-acid side chains participating in the formation of the dimer

Maximum contact distance considered for analysis = 3.5 Å		
From	To	Distance (Å)
Glu12 OE1	Lys280 NZ	3.2
Glu12 OE2	Lys280 NZ	3.0
Trp77 NE1	Gln211 O	3.0
Trp77 NE1	Glu212 O	3.5
Lys80 NZ	Glu212 OE1	2.9
Lys80 NZ	Glu212 OE2	2.9
Lys80 NZ	Lys280 O	3.4
Lys80 O	Lys280 NZ	3.0

to expose the catalytic site to facilitate calcium binding (Brunie *et al.*, 1985). The *C. atrox* crystallographic dimer is stabilized by five hydrogen bonds and hydrophobic interactions. Of these, out of a total of ten residues involved only three (Tyr52, Asn67 and Lys69) are conserved in myotoxin II. The myotoxin II dimer is stabilized by intermolecular hydrogen bonds involving Gln12, Trp77 and Lys80 (see Table 3), none of these residues are conserved in *C. atrox* PLA<sub>2</sub>.

#### The calcium-binding loop

In catalytically active PLA<sub>2</sub>'s, calcium is an essential cofactor. The ligated  $\text{Ca}^{2+}$  in the crystal structure of bovine pancreatic PLA<sub>2</sub> (Dijkstra *et al.*, 1981) is situated




Fig. 4(a). A stereoview of the dimer. Interactions are mainly between the amino acids located at the C-terminal end of the first helix and the loop region preceding the first  $\beta$ -strand of the  $\beta$ -wing. (b) A close-up view of this region in greater detail illustrating the side-chain and main-chain interactions which stabilize the dimer.

0.2 Å from the position of the  $\varepsilon$ -amino group in the superimposed App Lys49 structure (Scott *et al.*, 1992). Fig. 5 compares the same loop region from the myotoxin II [molecules 1 and 2 shown in Figs. 5(a) and 5(b), respectively] to that of App Lys49 PLA [Fig. 5(c)]. For comparison, Fig. 5(d) shows the homologous loop region from the catalytically active Asp49 *Naja naja atra* PLA<sub>2</sub>. The Lys49  $\varepsilon$ -amino groups in the three loop structures shown in Figs. 5(a)–(c) occupy the volume taken by the Ca<sup>2+</sup> ion in Fig. 5(d).

Comparison of the loop regions in the Lys49 PLA's shows that in myotoxin II Val31, Leu32 and Gly33 substitute for Trp, Gly and His, resulting in a very different loop conformation. Two of the three hydrogen bonds observed in the App Lys49 PLA<sub>2</sub> (Holland *et al.*,

1990) are conserved in both the monomers of myotoxin II. Furthermore, in the App Lys49 structure, the coordination of the amino group is completed by a tightly bound water molecule. In myotoxin II, no solvent atoms were observed in this region.

## Discussion

The structure of myotoxin II, a myotoxic Lys49 variant PLA<sub>2</sub> from *B. asper*, determined at 2.8 Å is very similar to the Lys49 variant from App (Holland *et al.*, 1990; Scott *et al.*, 1992) with which it shares 75% sequence identity (Francis *et al.*, 1991). In agreement with previous work, we find that the substitution of Asp49 by Lys49 results in the  $\varepsilon$ -amino group of Lys49 occupying the site normally filled by the calcium ion. This substitution and the consequent loss of Ca<sup>2+</sup>-binding ability, results in the lack of hydrolytic activity observed in these proteins (Maraganore *et al.*, 1984, Francis *et al.*, 1991). Site-directed substitution of Asp49 by Lys in porcine pancreatic PLA<sub>2</sub> also resulted in complete loss of catalytic activity (van den Berg *et al.*, 1989).

In all class I/II phospholipases, the amino-acid residues His48, Tyr52, Tyr73 and Asp99 are fully conserved. The Asp99/His48 pair, in conjunction with a bound water molecule, acts as a catalytic triad. Additionally, Asp99 is hydrogen bonded to the Tyr52 and Tyr73 side chains. This pattern of interconnected hydrogen bonds is referred to as the catalytic network (Kuipers, Franken, Hendricks, Verheij & de Haas, 1990). The relative positions of the amino acids in the catalytic network between the active PLA<sub>2</sub>'s and the inactive myotoxin II are structurally conserved (Fig. 6). Also shown in Fig. 6 is position 68, which in *N. naja atra* PLA<sub>2</sub> and myotoxin II are occupied by Pro, but in the case of App Lys49 PLA, is substituted by His. The functional significance of this substitution is unknown.

Myotoxin II forms a stable dimer in solution (Francis *et al.*, 1991), and we propose that the arrangement of the two monomers in the crystallographic asymmetric unit is




Fig. 5. Calcium-binding loop regions (amino acids 28–33 and 49) from myotoxin II molecule 1 (a), molecule 2 (b), App (c) and the catalytically active PLA<sub>2</sub> from *Naja naja atra*, which illustrates the coordination of the Ca<sup>2+</sup> ion (shown as a full sphere) in which a Asp49 replaces Lys (d).




Fig. 6. Results of the superpositioning of the amino acids forming the catalytic network. Molecules 1 and 2 from *B. asper* are shown as thick and thin lines, dashed and dotted lines represent the Asp49 PLA<sub>2</sub> from *Naja naja atra* and the App Lys49, respectively.

representative of the dimer in solution. The interactions between the monomers indicates a novel dimeric form in which the  $\beta$ -wing regions from each monomer interact, and the proposed lipid-binding face and residues involved in catalysis are exposed to the solvent. Although the amino acids forming the contacts in the myotoxin II dimer are conserved in App Lys49, and are in approximately the same relative orientations in the two crystal structures (Holland *et al.*, 1990; Scott *et al.*, 1992), they were not found to be involved in intermolecular interactions in the crystal structure of monomeric App. This suggests that other factors are involved in the formation and stabilization of the dimer. A number of studies have implicated the importance of the acylation of lysine residues as a mechanism to promote dimerization and a concomitant 200-fold increase in catalytic activity (Cho *et al.*, 1988; Tomasselli *et al.*, 1989); however, close examination of the electron-density map does not reveal the presence of acyl groups either on the lysines at the dimer interface, or in any other regions of the molecule. Table 3 shows that the dimer is stabilized by a total of eight salt bridges and hydrogen bonds between the two monomers, which has been shown to be stable in both 0.1% sodium dodecyl sulfate at 358 K and 2 M urea (Francis *et al.*, 1991). It is thus unlikely that such a stable structure can dissociate in solution.

Although myotoxin II is devoid of phospholipase activity, it retains potent myotoxic activity, causing myonecrosis by affecting the integrity of the plasma membrane of muscle fibers (Lomonte & Gutierrez, 1989). Attempts using amino-acid sequence comparisons to identify the region of the PLA<sub>2</sub> responsible for myotoxicity (Kini & Iwanaga, 1986) have not been successful in predicting myotoxicity in myotoxin II (Francis *et al.*, 1991). The same degree of myotoxicity and edema-inducing activity exists between myotoxins I and II (Gutierrez, Ownby & Odell, 1984), suggesting that phospholipase activity is not essential for these functions. Previous comparisons of myotoxic PLA<sub>2</sub> amino-acid sequences indicate that all have either three or four tyrosines between residues 112 and 121, a threonine at 112, and a lysine at position 38, all of which are not found in non-myotoxic PLA<sub>2</sub> sequences (Francis *et al.*, 1991). Based on the structure of PLA<sub>2</sub> from *C. atrox*, it has been suggested that Lys38 lies close to these C-terminal tyrosines, and may be implicated in myotoxic activity (Francis *et al.*, 1991). Interestingly, we find a network of hydrogen bonds in which the fully exposed Lys19 and Tyr109 from each monomer interact with the same amino acids from a symmetry-equivalent molecule. We are currently refining the structures of a number of other myotoxic PLA<sub>2</sub>-like proteins, and a comparison of the models may help to identify the region or regions conferring myotoxicity.

In conclusion, calcium ions are an essential co-factor for the hydrolysis of phospholipids by catalytically active

PLA<sub>2</sub>'s. A calcium-independent mechanism of membrane damage, without PLA<sub>2</sub> activity, has been demonstrated for myotoxin II (Rufini *et al.*, 1992). This indicates a novel mechanism for membrane damage, and the availability of the model for the myotoxin II will be useful in providing further insights on this activity.

Financial assistance by FAPESP and CNPq (Brazil) to RKA and RJW, and by CONICIT (Costa Rica) to JMG is gratefully acknowledged. Atomic coordinates and structure factors have been deposited with the Protein Data Bank (Bernstein *et al.*, 1977).\*

\*Atomic coordinates and structure factors have been deposited with the Protein Data Bank, Brookhaven National Laboratory (Reference: 1CLP, R1CLPSF). Free copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England (Reference: GR0379). At the request of the authors, the structure factors will remain privileged until 1 May, 1997.

## References

- ARNI, R. K. & GUTIERREZ, J. M. (1993). *Toxicon*, **31**, 1061–1064.
- BERG, C. J. VAN DEN, SLOTBOOM, A. J., VERHEIJ, H. M. & DE HAAS, G. H. (1989). *J. Cell. Biochem.* **39**, 379–390.
- BERNSTEIN, F. C., KOETZLE, T. F., WILLIAMS, G. J. B., MEYER, E. F. JR., BRYCE, M. D., RODGERS, J. R., KENNARD, O., SIMANOUCHI, T. & TASUMI, M. (1977). *J. Mol. Biol.* **112**, 535–542.
- BRÜNGER, A. T. (1988). In , edited by N. W. ISAACS & M. R. TAYLOR. Oxford: Clarendon Press.
- BRUNIE, S., BOLIN, J., GEWIRTH, D. & SIGLER, P. B. (1985). *J. Biol. Chem.* **260**, 9742–9749.
- CHO, W., TOMASSELLI, A., HEINRICKSON, R. L. & KEZDY, F. J. (1988). *J. Biol. Chem.* **263**, 11237–11241.
- CROWTHER, R. A. & BLOW, D. M. (1967). *Acta Cryst.* **23**, 544–548.
- VAN DEENAN, L. L. M. & DE HAAS, G. H. (1964). *Advances in Lipid Research*, Vol. 2, p. 167. New York: Academic Press.
- DENNIS, E. A. (1983). *Phospholipase A<sub>2</sub>: The Enzymes*, Vol. 16, pp. 307–353. New York: Academic Press.
- DHILLON, D. S., CONDREA, E., MARAGANO, J. M., HEINRICKSON, R. L., BENJAMIN, S. & ROSENBERG, P. (1987). *Biochem. Pharmacol.* **36**, 1723–1730.
- DUJKSTRA, B. W., KALK, K. H., HOL, W. G. J. & DRENTH, J. (1981). *J. Mol. Biol.* **147**, 97–123.
- DUJKSTRA, B. W., RENETSEDER, R., KALK, K. H., HOL, W. G. J. & DRENTH, J. (1983). *J. Mol. Biol.* **168**, 163–179.
- DUFTON, M. J. & HIDDER, R. C. (1983). *Eur. J. Biochem.* **137**, 545–551.
- FITZGERALD, P. M. D. (1988). *J. Appl. Cryst.* **21**, 273–278.
- FRANCIS, B., GUTIERREZ, J. M., LOMONTE, B. & KAISER, I. I. (1991). *Arch. Biochem. Biophys.* **284**, 352–359.
- FREEMONT, D. H., ANDERSON, D. H., WILSON, I. A., DENNIS, E. A. & XUONG, N.-H. (1993). *Proc. Natl Acad. Sci.* **90**, 342–346.
- GUTIERREZ, J. M., OWNBY, C. L. & ODELL, G. V. (1984). *Toxicon*, **22**, 115–128.
- HEINRICKSON, R. L., KREUGER, E. T. & KEIM, P. S. (1977). *J. Biol. Chem.* **252**, 4913–4921.
- HOLLAND, D. R., CLANCY, L. L., MUCHMORE, S. W., RYDEL, T. J., EINSPAHN, H. M., FINZEL, B. C., HEINRICKSON, R. L. & WATENPAUGH, K. D. (1990). *J. Biol. Chem.* **265**, 17649–17656.
- HOMSI-BRANDENBURGO, M. I., QUEIROZ, L. S., SANTO-NETO, H., RODRIGUES-SIMON, L. & GIGLIO, J. R. (1988). *Toxicon*, **26**, 615–627.

- HOWARD, A. J., GILLILAND, G. L., FINZEL, B. C., POULOS, T. L., OHLENDORF, D. H. & SALEMME, F. R. (1987). *J. Appl. Cryst.* **20**, 383–387.
- JONES, T. A. (1985). *Methods Enzymol.* **115**, 157–171.
- KINI, R. M. & IWANAGA, S. (1986). *Toxicon*, **24**, 895–905.
- KUIPERS, O. P., FRANKEN, P. A., HENDRICKS, R., VERHEIJ, H. M. & DE HAAS, G. H. (1990). *Protein Eng.* **4**, 199–204.
- LATTMAN, E. E. & LOVE, W. E. (1972). *Acta Cryst.* **B26**, 1854–1857.
- LIU, S. Y., YOSHIZUMI, K., ODA, N., OHNO, M., TOKUNAGA, F., IWANAGA, S. & KIHARA, H. (1990). *J. Biochem. (Tokyo)*, **107**, 400–408.
- LOMONTE, B. & GUTIERREZ, J. M. (1989). *Toxicon*, **27**, 725–733.
- MARAGANO, J. M., MERKUTA, G., CHO, W., WELCHES, W., KZEDY, F. J. & HEINRICKSON, R. L. (1984). *J. Biol. Chem.* **261**, 13839–13843.
- MARAGANO, J. M., POORMAN, R. A. & HEINRICKSON, R. L. (1987). *J. Protein Chem.* **6**, 173–189.
- RAMACHANDRAN, G. N. & SASHISEKHARAN, S. (1965). *Adv. Protein Chem.* **23**, 283–437.
- RAMINEZ, F. & JAIN, M. K. (1991). *Protein Struct. Funct. Genet.* **9**, 229–239.
- RENETSEDER, R., BRUNIE, S., DIJKSTRA, B. W., DRENTH, J. & SIGLER, P. B. (1985). *J. Biol. Chem.* **260**, 11627–11634.
- RUFINI, S., CESARONI, P., DESIDERI, A., FARIAS, R., GUBENSEK, F., GUTIERREZ, J. M., LULY, R., MASSOUD, R., MORENO, R. & PEDERSEN, J. Z. (1992). *Biochemistry*, **31**, 12424–12430.
- SCOTT, D. L., ACHARI, A., VIDAL, J. C. & SIGLER, P. B. (1992). *J. Biol. Chem.* **267**, 22645–22657.
- SCOTT, D. L., WHITE, S. P., OTWINOWSKI, Z., YUAN, W., GELB, M. H. & SIEGLER, P. B. (1990). *Science*, **250**, 1541–1546.
- SHEN, B. W., TSAO, F. H. C., LAW, J. H. & KEZDY, F. J. (1975). *J. Am. Chem. Soc.* **97**(5), 1205–1208.
- TOMASSELLI, A. G., HUI, J., FISHER, J., ZWCHER-NEELY, H., REARDON, I. M., DRIAKU, E., KEZDY, F. J. & HEINRICKSON, R. L. (1989). *J. Biol. Chem.* **264**, 10041–10047.
- WAITE, M. (1987) in *The Phospholipases: Handbook of Lipid Research*, edited by M. WAITE, pp. 155–241. New York: Plenum Press.
- WERY, J. P., SCHEVITZ, R. W., CLAWSON, D. K., BOBBITT, J. L., DOW, E. R., GAMBOA, G., GOODSON, T., HERMANN, R. B., KRAMER, R. M., MCCLURE, D. B., MIHELICH, E. D., PUTNAM, J. E., SHARP, J. D., STARK, D. H., TEATER, C., WARRICK, M. W. & JONES, N. D. (1991). *Science*, **352**, 79–82.
- WHITE, S. P., SCOTT, D. L., OTWINOWSKI, Z., GELB, M. H. & SIGLER, P. B. (1990). *Science*, **250**, 1560–1566.
- YOSHIZUMI, K., LIU, S. Y., MIYATA, T., SAITA, S., OHNO, M., IWANAGA, S. & KIHARA, H. (1990). *Toxicon*, **28**(1), 43–45.